HC Wainwright & Co. Upgrades Context Therapeutics to Buy, Announces $5 Price Target
HC Wainwright & Co. Upgrades Context Therapeutics to Buy, Announces $5 Price Target
HC Wainwright & Co.將Context Therapeutics升級爲收購,宣佈5美元的目標
HC Wainwright & Co. analyst Emily Bodnar upgrades Context Therapeutics (NASDAQ:CNTX) from Neutral to Buy and announces $5 price target.
HC Wainwright & Co.分析師Emily Bodnar 將Context Therapeutics(納斯達克股票代碼:CNTX)從中性上調至買入,並宣佈5美元的目標價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。